News

More research is essential to improve protocols for diagnosing Alzheimer’s disease in people with Down syndrome, but the ability to identify and care for those patients is enhanced significantly if clinicians are aware of specific circumstances and use a multi-disciplinary treatment strategy. Those findings are included in a study titled …

NeuroTherapia, a Cleveland Clinic spin-off biotech company, has received a $1.7 million funding commitment from the Alzheimer’s Drug Discovery Foundation to advance its lead drug candidate NTRX-07 — a selective cannabinoid type 2 (CB2) receptor agonist that can be orally administered — toward human clinical trials. This therapy targets…

One of the pathological hallmarks of Alzheimer’s disease is the accumulation of the protein, amyloid beta, in neurons, leading to the formation of plaques that impair brain function. Exactly how amyloid beta enters and becomes toxic to neuron, or nerve, cells, however, is a matter of debate — with a new…

The Association for Frontotemporal Degeneration (AFTD) is hosting its inaugural Hope Rising Benefit  Sept. 29, to increase awareness of frontotemporal degeneration (FTD) and raise funds to support AFTD’s collaborative research, education for healthcare professionals and advocacy for affordable services. FTD is a disease process that damages the temporal…

Researchers report identifying the molecular mechanisms responsible for activating the neuroglobin gene, which scientists think may protect people from developing Alzheimer’s disease. Moreover, the researchers suggest that scientists should explore ways of activating the gene as potential treatments for Alzheimer’s disease. The study, titled “Identification of a novel…

September 21 was World Alzheimer’s Day, a fitting occasion to announce that a recent study from Finnish and Swedish researchers has confirmed that MedUni Vienna scientists were right: Multimodal everyday training does, indeed, have a beneficial effect upon cognitive abilities such as planning and implementing projects. That is true for…

Cure Alzheimer’s Fund recently announced that it has awarded over $6 million in research grants this year to support scientific projects working to improve our knowledge of Alzheimer’s disease (AD) and to develop potential treatments. In total in 2016, so far, the organization has funded 29 projects in the U.S. and…

Twenty-five years have passed since researchers launched the idea that Alzheimer’s is a direct result of clumps of amyloid-beta littering the brain. The amyloid hypothesis of Alzheimer’s disease, as it is called, quickly raised hopes among researchers and patients alike that the dreaded disease would soon be under our control. But…

Researchers at the University of British Columbia (UBC) have found that many online resources about how to prevent Alzheimer’s disease (AD) are not accurate and can mislead readers. In a survey of online resources, UBC researchers found that a series of websites offered poor advice and one in five was…

The U.S. Food and Drug Administration (FDA) issued a draft guidance in 2013 to encourage research  in people at the earliest stages of Alzheimer’s disease, with no symptoms or no obvious symptoms. The update has had effect, with new clinical trials looking at Alzheimer’s patients without noticeable dementia, when they…